{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-031820","form_type":"8-K/A","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.759966+00:00","generated_at":"2026-06-13T15:32:47.761871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Roivant corrects Immunovant TED Phase 3 data timeline to H1 2025; reports Q4 revenue $27.4M, loss $0.05/share","bullets":["Corrected timeline for Immunovant's Phase 3 TED trials: topline data expected in H1 2025 (previously misstated).","Q4 product revenue from VTAMA $13.7M; fiscal year VTAMA revenue $28.0M; over 170,000 prescriptions since launch.","Cash and equivalents $1.7B as of March 31, 2023; cash runway into H2 2025.","RVT-3101 Phase 2b UC data showed improved efficacy from week 14 to week 56; Phase 2 Crohn's study initiated.","Net loss attributable to Roivant $33.6M ($0.05 per share) for Q4 vs $270.1M loss year ago; loss from continuing ops $175.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-031820","json":"https://secwatch.observer/filing/0001140361-23-031820.json","markdown":"https://secwatch.observer/filing/0001140361-23-031820.md","text":"https://secwatch.observer/filing/0001140361-23-031820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/0001140361-23-031820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/brhc20055123_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:32:47.761871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fee760a2e9fba8dcc614272119f4d0ead2dd46f","claim":"Roivant Sciences Ltd. reported financial results for fourth quarter and fiscal year ended March 31, 2023.","evidence_excerpt":"Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/0001140361-23-031820-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}